These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8489566)

  • 41. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses.
    Tröger U; Martens J; Meyer FP; Hoffmann A; Terhaag B
    Arzneimittelforschung; 1995 Dec; 45(12):1266-70. PubMed ID: 8595082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dissolution kinetics of bezafibrate in two solid forms for oral administration.
    Cadorniga R; Hernanez MT; Negro S; Burgos ML; Molina IT
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():371-8. PubMed ID: 1820910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects.
    Cardot JM; Chaumont C; Dubray C; Costantini D; Aiache JM
    Br J Clin Pharmacol; 2004 Oct; 58(4):345-51. PubMed ID: 15373926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioavailability of amfepramone hydrochloride sustained release pellets formulation in healthy subjects.
    Dangor CM; Beckett AH; Veltman AM
    Arzneimittelforschung; 1987 Jun; 37(6):736-9. PubMed ID: 3663274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood levels and bioavailability of ascorbic acid after administration of a sustained-release formulation to humans.
    Sacharin R; Taylor T; Chasseaud LF
    Int J Vitam Nutr Res; 1977; 47(1):68-74. PubMed ID: 844951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)].
    Maier-Lenz H; Ringwelski L; Windorfer A
    Arzneimittelforschung; 1980; 30(2):320-4. PubMed ID: 6769443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative bioavailability of sustained-release and uncoated aspirin tablets.
    Karahalios WJ; Sawyer WT; Rittase RA; Maynard SA
    Am J Hosp Pharm; 1981 Nov; 38(11):1754-6. PubMed ID: 7304632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Relative bioavailability of a vincamine retard formulation. Pharmacokinetic study in normal subjects (author's transl)].
    Erking W; Lücker PW; Metz G; Specker M; Wetzelsberger K
    Arzneimittelforschung; 1978; 28(12):2332-6. PubMed ID: 582951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacokinetics of two theophylline sustained-release preparations in healthy humans].
    Keller A; Schulz HU
    Arzneimittelforschung; 1994 Nov; 44(11):1233-6. PubMed ID: 7848337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients.
    Neugebauer G; Platt D; Vömel T; Lösch W
    Klin Wochenschr; 1988 Mar; 66(6):250-6. PubMed ID: 3367617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation.
    Karttunen P; Uusitupa M; Lamminsivu U
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):31-6. PubMed ID: 6832864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study of pharmacokinetics and pharmacodynamics of two preparations of metoclopramide.
    Harrison FJ; Heirler F; Scherer J; Wulsch A; Galiano A; Hornauer M; Kelly J
    Arzneimittelforschung; 1994 Apr; 44(4):519-21. PubMed ID: 8011007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Butriptyline: human pharmacokinetics and comparative bioavailability of conventional and sustained release formulations.
    Bourgouin J; Gagnon MA; Elie R; Dvornik D; Gonzalez R; Kraml M
    Biopharm Drug Dispos; 1981; 2(2):123-30. PubMed ID: 6894708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of once-daily verapamil: comparative bioavailability of two sustained-release formulations.
    Muirhead DC; Norris RJ; Cockayne D; Hill GW
    Br J Clin Pract Suppl; 1988 Apr; 60():14-9. PubMed ID: 3151264
    [No Abstract]   [Full Text] [Related]  

  • 55. Relative bioavailability of a standard and a sustained-release quinidine tablet.
    Gibson DL; Smith GH; Koup JR; Stewart DK
    Clin Pharm; 1982; 1(4):366-8. PubMed ID: 7185532
    [No Abstract]   [Full Text] [Related]  

  • 56. Relative bioavailability and release pattern of whole and halved sustained-release theophylline tablets.
    Leeds NH; Gal P; Purohit AA; Walter JB
    Clin Pharm; 1982; 1(2):163-4. PubMed ID: 7185516
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    Ledermann H; Kaufmann B
    J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacokinetics and relative bioavailability of a new oral sustained-release form of mexiletine in healthy subjects].
    Santoni Y; Bruno R; Fornaris M; Egre A; Danays T; Cano JP
    Therapie; 1983; 38(4):341-4. PubMed ID: 6648880
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetic characterization of controlled-release formulations.
    Steinijans VW
    Eur J Drug Metab Pharmacokinet; 1990; 15(2):173-81. PubMed ID: 2200687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liberation of lithium from sustained release preparations. A comparison of seven registered brands.
    Heim W; Oelschläger H; Kreuter J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1994 Jan; 27(1):27-31. PubMed ID: 8159780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.